BMY · News · 20260804N
Acquisition / Partnership / Divestiture
BRISTOL MYERS SQUIBB CO · 2026-08-04 · Importance 71 · Surprise 60 · Contradicted
Bristol Myers Squibb was reported to have held early-stage merger discussions with AstraZeneca for a potential combination valued at approximately $400 billion. The proposed transaction would combine major oncology, immunology, hematology, and neuroscience portfolios and could help BMS address anticipated patent expirations for Eliquis and Opdivo by 2028. Reuters and other reports subsequently cited a senior source denying that discussions ever occurred; analysts noted potential antitrust scrutiny, particularly from the U.S. Federal Trade Commission, because of overlapping oncology and immunotherapy products.
Key facts
- U.K. drugmaker AstraZeneca and New Jersey-based Bristol Myers Squibb are reportedly in early-stage talks for a potential $400 billion merger. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| liability | negative | contingent | — | U.K. drugmaker AstraZeneca and New Jersey-based Bristol Myers Squibb are reportedly in early-stage talks for a potential $400 billion… |